Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 11, 2000

View Archived Issues

Testosterone buccal tablet enters late-stage clinical testing

Dimethaid receives approval for Pennsaid lotion in U.K.

Oxford GlycoSciences and Glaxo Wellcome enter proteomics alliance

Neurochem demonstrates proof of concept for AD compound

Immunosuppressive drug in development at Isotechnika shows promise in phase I

Biogen licenses novel neurotrophic protein from NsGene

BMS extends license for PathoGenome database

Viventia Biotech's H11 enters phase I/II oncology trial

ARANESP effective given once weekly, and possibly less frequently, in treating anemia

Early clinical evidence of efficacy, safety of UCN-01 plus fludarabine phosphate in CLL

Gilead obtains rights to Glaxo Wellcome TS inhibitor

Apomate imaging agent receives orphan drug status from FDA

ASH news: proteasome inhibitor LDP-341 as attractive new drug for multiple myeloma, CLL

Heparin inhibition of complement activation: comparative effects of Neutralase and protamine

Synaptic discovers peptide ligand that potentially inhibits metastasis

FDA approves Protopic for the treatment of eczema

New combretastatin prodrug displays enhanced solubility and antitumor activity

Positive results for new glycopeptide show dramatic and sustained reductions in bacterial load

Myobloc is first FDA-approved treatment for cervical dystonia

Derivatives of 3-deoxy-desmycosin with antimicrobial activity designed by Pliva

New macrolides from Pliva exhibit broad spectrum of activity

Pyrazole-based antiinflammatory agents patented by Dr. Reddy's team

Nycomed Imaging identifies novel X-ray contrast agents

Inhibitors of Lp-PLA2 from SB reportedly useful for atherosclerosis

AstraZeneca presents new carboxypeptidase U inhibitors and use thereof

Highly selective dopamine D4 receptor partial agonists identified at German university

ConjuChem initiates phase I trial of novel analgesic product

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...